Mark Chao

Mark Chao

Health Technology
Consumer Services
Finance

Profile

Mark Chao is the founder of Hepatx Corp.
(2015), Forty Seven LLC (2014), and TenSixteen Bio, Inc. (2021).
Dr. Chao is also the founder of Gilead Sciences, Inc. Dr. Chao is currently an Advisor at Bioverge Funds Management LLC, a Venture Partner at Foresite Labs LLC, a Scientific Advisory Board Member at IconOVir Bio, Inc., and a Scientific Advisory Board Member at TigaTx, Inc. Education includes a graduate degree from Stanford University (2011), an undergraduate degree from Case Western Reserve University (2004), and both a graduate degree and a doctorate from Stanford University School of Medicine (2011).

Mark Chao active positions

CompaniesPositionStart
FORTY SEVEN, INC. Founder 2013-12-31
Private Equity Investor 2020-12-31
Consultant / Advisor 2021-11-30
Consultant / Advisor 2020-04-30
Consultant / Advisor -

Former positions of Mark Chao

CompaniesPositionEnd
Chief Executive Officer 2022-12-31
GILEAD SCIENCES, INC. Founder -
Founder -
See the detail of Mark Chao's experience

Training of Mark Chao

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

88

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Consumer Services

Consumer Services

Health Technology

Consumer Services

Finance

Technology Services

Commercial Services

Health Technology

Health Technology

Health Technology